TWA
ADPT icon

TCI Wealth Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

TCI Wealth Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-494
Closed -$4.36K – 236
2023
Q1 		$4.36K Hold
494
– – ﹤0.01% 1623
2022
Q4 		$3.77K Buy
+494
New +$3.84K ﹤0.01% 1715
2022
Q2 		– Sell
-32
Closed – – 2248
2022
Q1 		$0 Buy
+32
New +$503 ﹤0.01% 2199
2021
Q1 		– Sell
-180
Closed -$11K – 2156
2020
Q4 		$11K Buy
+180
New +$9.28K ﹤0.01% 617

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

TCI Wealth Advisors's ADPT Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 494 shares — an estimated $4.36K sold.

TCI Wealth Advisors first reported a position in ADPT in Q4 2020 and held it in 4 quarters. The position peaked at $11K in Q4 2020. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 494 Adaptive Biotechnologies shares in Q2 2023, an estimated $4.36K.
  • TCI Wealth Advisors first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 4 quarters.
  • TCI Wealth Advisors's Adaptive Biotechnologies position peaked at $11K in Q4 2020.
  • 210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.